China tells medical institutions to stop using Huahai heart drug
By Brenda Goh and David Stanway SHANGHAI (Reuters) – China’s health regulator has...
Read More
Updated
U.S. court expedites Indivior rival’s appeal to re-launch generic drug
(Reuters) – Indivior said on Monday a U.S. Court expedited a generic rival’s appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker’s blockbuster opioid...
Read MoreFDA declines to approve Insys Therapeutic’s opioid painkiller
(Reuters) – Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys shares slid nearly 9 percent to $6.62 on Friday,...
Read More
China says vaccine maker Changsheng broke manufacturing rules, faked records: Xinhua
BEIJING (Reuters) – China’s cabinet investigation group has found that vaccine maker...
Read More
Hong Kong clinics prepare for influx of mainland visitors after China vaccine scandal
By Trista Shi and Holly Chik HONG KONG (Reuters) – Henry Yeung, a pediatrician and president...
Read More
Viral content: vaccine scandal tests Beijing’s grip on information control
By Adam Jourdan and Pei Li SHANGHAI/BEIJING (Reuters) – A Chinese vaccine scandal has laid...
Read More
Britain to legalize medicinal use of cannabis
LONDON (Reuters) – Britain is to allow doctors to prescribe medicinal cannabis, following a...
Read More
New drugs shine as AstraZeneca treads path back to growth
By Ben Hirschler LONDON (Reuters) – AstraZeneca’s new drugs performed strongly in the...
Read MoreInvestors turn wary on Biogen/Eisai Alzheimer’s drug results
By Julie Steenhuysen and Sam Nussey CHICAGO/TOKYO (Reuters) – Shares of Eisai Co Ltd plunged as much as 21 percent after the results of its experimental Alzheimer’s drug being developed with partner Biogen Inc failed...
Read More
Amgen’s new migraine drug hits insurance hurdles
By Deena Beasley (Reuters) – Amgen Inc’s push to get patients on its new $575 a month...
Read MoreAcorda loses bid for U.S. court order halting generic Ampyra sales
By Jan Wolfe (Reuters) – A U.S. appeals court on Wednesday denied a request by Acorda Therapeutics Inc for a temporary court order blocking generic drug companies from launching lower-cost versions of its multiple...
Read More
Europe adopts new pilot mental health rules after Germanwings crash
BERLIN (Reuters) – Three years after the Germanwings crash in which a pilot deliberately...
Read More
GSK bets $300 million on genetics as CEO plays down break-up talk
By Ben Hirschler LONDON (Reuters) – GlaxoSmithKline aims to turbo-charge its drug discovery...
Read MoreBritish drugmaker Indivior’s shares hit by copycat, new drug worries
By Justin George Varghese (Reuters) – Indivior shares fell more than 20 percent after the British drugmaker warned of a bigger-than-expected blow from a copycat of its top opioid addiction treatment and posted weak initial...
Read More
Prince Harry joins Elton John to launch HIV campaign targeting men
(This July 24 story corrects name of U.S. government’s HIV program to PEPFAR in the...
Read More
Biogen easily tops Street estimates on Spinraza sales, raises forecast
By Manas Mishra (Reuters) – Biogen Inc <BIIB.O> reported far better-than-expected...
Read More
U.S. to narrow opioid bribe case against Insys founder, others
By Nate Raymond BOSTON (Reuters) – U.S. prosecutors on Tuesday said they will narrow a case...
Read More
Massachusetts to probe e-cigarette maker Juul over sales to minors
By Nate Raymond BOSTON (Reuters) – Massachusetts is investigating e-cigarette maker Juul...
Read More
Lilly plans Elanco IPO, posts quarterly profit above estimates
By Tamara Mathias and Michael Erman (Reuters) – Eli Lilly and Co said on Tuesday it would...
Read More
Congo declares Ebola flare-up over after rapid response
By Edward McAllister DAKAR (Reuters) – Democratic Republic of Congo on Tuesday declared an...
Read More